PureTech Health (LON:PRTC) Reaches New 12-Month Low – What’s Next?

Shares of PureTech Health plc (LON:PRTC) reached a new 52-week low on Thursday . The stock traded as low as GBX 134.80 ($1.66) and last traded at GBX 136.40 ($1.68), with a volume of 325557 shares. The stock had previously closed at GBX 138 ($1.70).

Analyst Ratings Changes

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.60) price objective on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Stock Down 1.2 %

The stock’s 50 day moving average is GBX 157.66 and its 200 day moving average is GBX 159.51. The company has a market capitalization of £326.57 million, a PE ratio of -593.04 and a beta of 1.02. The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.